Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Belumosudil with Itraconazole, Rifampicin, Rabeprazole, and Omeprazole
NCT03530995Phase 1Completed
- Sponsor
- Kadmon
- Start
- Apr 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 cohorts), sponsored by Kadmon. Primary endpoints: Maximum Plasma Concentration (Cmax) of KD025 and Metabolites and Area Under the Curve (AUC) of KD025 and Metabolites. Started Apr 2018; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03530995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530995.